Pro-Dex (NASDAQ:PDEX) Upgraded at StockNews.com

Pro-Dex (NASDAQ:PDEX) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Separately, Ascendiant Capital Markets increased their price objective on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Pro-Dex Trading Down 0.6 %

Shares of PDEX opened at $49.44 on Friday. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The stock has a market cap of $161.17 million, a PE ratio of 32.10 and a beta of 0.56. Pro-Dex has a 1 year low of $16.18 and a 1 year high of $54.84. The stock has a 50 day simple moving average of $39.86 and a 200-day simple moving average of $27.70.

Insider Buying and Selling at Pro-Dex

In other Pro-Dex news, CFO Alisha Charlton sold 1,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $40.02, for a total value of $40,020.00. Following the transaction, the chief financial officer now owns 15,339 shares of the company’s stock, valued at approximately $613,866.78. The trade was a 6.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 47.50% of the company’s stock.

Institutional Trading of Pro-Dex

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its holdings in shares of Pro-Dex by 5.1% in the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares in the last quarter. Bard Associates Inc. boosted its position in Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 2,031 shares during the last quarter. FMR LLC increased its stake in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after buying an additional 900 shares during the period. 15.28% of the stock is currently owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.